Celltrion Healthcare: UK Lags behind Most of Europe in Access to Biologics for Patients with Rheumatoid Arthritis
Celltrion Healthcare calls for the NHS to consider lowering the threshold for starting biologics in patients with rheumatoid arthritis (RA) and to put plans in place to increase patient access to biological treatment.
According to recent findings published in the Annals of the Rheumatic Diseases, disease activity and the use of biological disease-modifying anti-rheumatic drugs among patients with RA vary from country to country, due to different contributing factors, such as per capita GDP, drug affordability and reimbursement policies.1
There are set thresholds in disease activity before biologics can be used in RA patients, but these thresholds vary across Europe. The percentage of patients who are treated with an anti-TNF-α (an effective class of treatment that reduces inflammation and pain) is 24% or higher in countries such as Italy and France, however, in the UK this drops to just 15%. This is because in the UK a patient must have a higher DAS-28 (a measure of how severe the disease is) threshold of 5.1 compared to only 3.2 in other European countries. 2,3,4 Despite the National Institute for Health and Care Excellence (NICE) widely acknowledging that appropriate biological treatments are clinically effective for all subgroups of RA patients, access to these therapies remains restricted in UK on grounds of cost-effectiveness.5
Speaking at the Health and Care Innovation Expo 2018 taking place on 5 and 6 September, Dr. Ben Parker, Consultant Rheumatologist, Manchester University Hospitals, NHS Foundation Trust says, “A UK patient’s burden of disease must be much more severe before they qualify for biologic therapy, compared to a French patient. As a treating physician, I strongly believe that this inequality needs to be addressed so that our patients can realize the same benefits of early treatment as their European neighbors.”
The National Rheumatoid Arthritis Society (NRAS) and British Society for Rheumatology (BSR) concur that in the UK “eligibility criteria (DAS-28 of more than 5.1) are set too high.” and state, within their “Biologics…The Story So Far” publication, that “The BSR and others, including NRAS, will continue to make the case to NICE for reducing the required DAS-28 score from 5.1”.6
According to NHS’s recent savings data, NHS England saved £324m in the last financial year by switching from using 10 higher priced medicines to better value biosimilars and generic medicines which are considered to be equally effective and safe alternatives. Switching patients to biosimilars of these biologics led to significant cost savings: infliximab biosimilars delivered £99.4 million in savings, etanercept biosimilars delivered £60.3 million, and rituximab biosimilars delivered £50.4 million, for a cumulative savings of over £220 million in cancer and autoimmune diseases such as rheumatoid arthritis and inflammatory bowel diseases.7
Mr. HoUng Kim, Head of Strategy and Operations at Celltrion Healthcare said, “We have identified clear disparities in access to biologics across Europe. Patients diagnosed with less than severe disease activity should be able to get just as good and cost-effective benefit from biologics as patients with severely active disease, as this will help them achieve a better quality of life. With the proven savings, gained through the use of biosimilars, this could be a real opportunity for the NHS to address these concerning inequalities.”
Notes to editors:
About rheumatoid arthritis
In Europe, more than 2.9 million people have rheumatoid arthritis (RA), many of whom are of working age. On average, every third person with RA becomes work disabled and up to 40 per cent leave work completely within 5 years of diagnosis.8 Although there is no cure for RA, there are many treatments that can reduce inflammation and ease pain. As with all rheumatic diseases early diagnosis and intervention is key.
About CT-P13 (biosimilar infliximab)
CT-P13 is developed and manufactured by Celltrion, Inc. and was the world’s first monoclonal antibody biosimilar approved by the European Commission (EC). It is indicated for the treatment of eight autoimmune diseases including rheumatoid arthritis and IBD. It was approved by the EC under the trade name Remsima® in September 2013 and launched in major EU countries in early 2015. The US FDA approved CT-P13 in April 2016 under the trade name Inflectra®. CT-P13 is approved in more than 88 countries (as of August 2018) including the US, Canada, Japan and throughout Europe.
About Celltrion Healthcare
Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavors to offer high-quality cost-effective solutions through an extensive global network that spans more than 120 different countries. For more information please visit: http://www.celltrionhealthcare.com/
1 Bergstra S, Branco J, Vega-Morales D et al. Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry. ARD 6 July 2018. Available at https://ard.bmj.com/content/early/2018/07/06/annrheumdis-2018-213289 [Last accessed August 2018].
2 Deighton C, Hyrich K, Ding T et al. BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology 2010; 49 (6): 1197–1199.
3 Jonsson B, Kobelt G, Smolen J. The burden of rheumatoid arthritis and access to treatment: uptake of new therapies. Eur J Health Econ 2008; 8 (2): 61–86.
4 Global Data Forecast and Market Analysis – Rheumatoid Arthritis. Published January 2017 [Last accessed August 2018]
5 NICE Technology appraisal guidance [TA375]. Published: 26 January 2016. Available at https://www.nice.org.uk/guidance/ta375 [Last accessed August 2018].
6 National Rheumatoid Arthritis Society. Biologics... The Story So Far. September 2013. Pg 29. Available at https://www.nras.org.uk/data/files/Publications/Biologics-.pdf [Last accessed August 2018].
7 NHS Improvement UK. The NHS saves £324 million in a year by switching to better value medicines. Published 31 July 2018. Available at https://improvement.nhs.uk/news-alerts/nhs-saves-324-million-year-switching-better-value-medicines/ [Last accessed August 2018].
8 NRAS, European Fit for Work Report. Available at www.nras.org.uk/european-fit-for-work-report. [Last accessed August 2018].
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Telefónica Deutschland Selects SIAE MICROELETTRONICA for Turn-Key DCN Migration Services in Germany19.11.2018 11:00 | Tiedote
Telefónica Deutschland , a leading integrated telecommunications provider in Germany awards SIAE MICROELETTRONICA, a long-term strategic partner for wireless transmission solutions, a turn-key contract for DCN (Data Communication Networks) migration services across its backhaul network. Following the successful acquisition of E-Plus, Telefónica Deutschland new backhaul network counts over 30.000 microwave radio links from three different vendors, including SIAE MICROELETTRONICA. In preparation for a potential 5G launch in the future, Telefónica is taking steps to simplify operations and maximize performances and coherence across its network. With these activities Telefónica plans to update its DCN by implementing a new common-DCN architectural model. The migration services entrusted to SIAE MICROELETTRONICA include project- management, IP network design, new-model implementation and operation service delivery. The cluster-by-cluster migration process consists of a mix of remote configu
Dentons Global Chairman and Global Chief Executive Officer Re-Elected19.11.2018 11:00 | Tiedote
Dentons, the world's largest law firm, announced today that Joseph Andrew and Elliott Portnoy have been re-elected to three-year terms as Global Chairman and Global Chief Executive Officer, respectively. They have led the firm together since its formation in March 2013. Messrs. Andrew and Portnoy ran without opposition and have been the entrepreneurial drive and architects of Dentons’ client-centric strategy and polycentric approach to law firm management, resulting in a period of unprecedented growth while many law firms are contracting as they are buffeted by the changes shaping the legal profession globally. Under their leadership, Dentons has grown into the world’s largest law firm with more than 9,600 lawyers operating in 174 locations and 78 countries. During this same time, the firm has successfully completed dozens of business combinations throughout markets in Africa, ASEAN, Australia, Canada, Caribbean, China, Europe, Latin America, Middle East, United Kingdom and United Stat
Biosense Webster Launches Report - The Burden of Atrial Fibrillation: Understanding the Impact of the New Millennium Epidemic Across Europe19.11.2018 09:00 | Tiedote
Biosense Webster EMEA, a Division of Johnson & Johnson Medical NV/SA and leader in the treatment of Atrial Fibrillation (AF) has today, during AF Association Global AF Aware Week, published a report that uncovers the growing burden of AF on patients, caregivers and healthcare systems across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181118005008/en/ The new report is calling for greater awareness and emphasis on the scale and impact of AF which is fast becoming one of the world’s most significant health issues. The new millennium epidemic not only disrupts the quality of life for the 11 million people across Europe who suffer from AF, but also costs healthcare systems up to €3,286 million annually across European countries.2-7 AF is characterized by an irregular and often fast heart rhythm that results in uncoordinated contraction of the top two chambers of the heart. The irregular heart rhythm may cause blood cl
China National Medical Products Administration (NMPA) Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for Chronic Hepatitis B Virus (HBV) Infection19.11.2018 06:00 | Tiedote
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the China National Medical Products Administration (NMPA) has approved Vemlidy® (tenofovir alafenamide, TAF) 25 mg, a once-daily treatment for chronic hepatitis B in adults and adolescents (aged 12 years and older with body weight at least 35 kg). Vemlidy is a novel, targeted prodrug of tenofovir that has demonstrated antiviral efficacy similar to Gilead’s Viread® (tenofovir disoproxil fumarate, TDF) 300 mg but at one-tenth of the dose. Data show that because Vemlidy has greater plasma stability and more efficiently delivers tenofovir to hepatocytes compared to Viread, it can be given at a lower dose, resulting in less tenofovir in the bloodstream. In clinical trials, Vemlidy demonstrated improved renal and bone laboratory safety parameters compared to Viread. “With the approval of Vemlidy, physicians can now offer their patients a treatment that retains the efficacy of TDF while improving renal and bone safety parameters in cli
Celltrion Healthcare: Biosimilars Have the Potential to Deliver Dramatic Cost Savings for US and European Healthcare Systems19.11.2018 03:01 | Tiedote
Celltrion Healthcare outlined their vision of ‘shaping future healthcare by improving access to biosimilars’ at the 5th Annual Biosimilars USA Conference in New Jersey, US. Biosimilars offer healthcare providers and patients greater treatment choice and value, better access to treatments and improved patient outcomes. According to data provided by IMS Health, biosimilars could lead to cumulative savings of up to 107 billion USD by 2020 in the United States (US) and the top five European Union (EU) countries.1 The EU has made significant progress in unlocking the potential of biosimilars through continuous education of providers, payers and patients. This has been critical to EU biosimilar acceptance but has not been seen in the US, which has lagged behind. During a presentation on the opportunities and challenges presented by the use of biosimilars in the US, Celltrion Healthcare highlighted several challenges affecting the uptake of biosimilars within the US market. Both physicians an
Abu Dhabi to Host Interfaith Alliance For Safer Communities: Child Dignity in the Digital World Forum on 19 November17.11.2018 16:40 | Tiedote
Held under the patronage of His Highness Sheikh Mohammed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Deputy Supreme Commander of the UAE Armed Forces, the UAE will host the first edition of the Interfaith Alliance For Safer Communities Forum on November 19-20 in recognition of the country’s leading role in promoting tolerance and interfaith dialogue. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181117005008/en/ His Highness Sheikh Mohammed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Deputy Supreme Commander of the UAE Armed Forces (Photo: AETOSWire) The forum will host 450 guests including religious leaders, NGOs and heads of industry to discuss ongoing social challenges and develop comprehensive solutions for protecting youth from cybercrime. The Interfaith Alliance For Safer Communities Forum is an expansion of the Child Dignity in the Digital World Congress which was held in October 2017 in the Vatican, an
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme